Baxter Q2 GAAP EPS rises 8% to $0.26; net sales increase 5% to $2.96 billion

Reuters2026/07/30 11:35

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Baxter posts Q2 2026 net sales of USD 2.96 billion, up 5% year over year; GAAP diluted EPS was USD 0.26.
GAAP net income from continuing operations rose 11% to USD 135 million; free cash flow was USD 181 million.
Medical Products & Therapies net sales climbed 7% to USD 2.08 billion; Healthcare Systems & Technologies increased 4% to USD 801 million.
CEO Andrew Hider said results beat expectations, helped by an IEEPA tariff refund; Novum IQ LVP shipment and installation hold weighed on Infusion Systems.
Full-year 2026 outlook raised to GAAP sales growth of 3%-4%; adjusted diluted EPS lifted to USD 1.95-USD 2.15.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Baxter International Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202607300715BIZWIRE_USPR_____20260728_BW073525) on July 30, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Baxter Q2 GAAP EPS rises 8% to $0.26; net sales increase 5% to $2.96 billion

You may also like

Crypto prices